POOR OUTCOME OF TWO CHILDREN WITH RELAPSED STATE STAGE IV ALVEOLAR RHABDOMYOSARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

REFERENCES

• Crist W, Gehan E A, Ragab A H. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995; 13: 610–630, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Miller D V, Coffin C M, Zhou H. Rhabdomyosarcoma arising in the hand or foot: a clinicopathologic analysis. Pediatr Dev Pathol. 2004; 7: 361–339, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Seeger R C, Reynolds C P. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am. 1991; 38: 393–424, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Emminger W, Emminger-Schmidmeier W, Hawliczek R, Peters C, Hocker P, Gadner H. High-dose melphalan, etoposide +/− carboplatin (MEC) combined with 12-gray fractionated total-body irradiation in children with generalized solid tumors. Pediatr Hematol Oncol. 1991; 8: 13–22, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shuster J J, Cantor A B, McWilliams N. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol. 1991; 9: 1045–1049, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pinkerton C R, Groot-Loonen J, Barrett A. Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas. Br J Cancer. 1991; 64: 381–385, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pinkerton R. [Massive chemotherapy followed by bone marrow graft in pediatric oncology: arguments against]. Bull Cancer. 1995; 82: 42–45, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Burdach S, Jurgens H, Peters C. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol. 1993; 11: 1482–1488, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Hartmann O, Pinkerton C R. The role of megatherapy with autologous bone marrow rescue in solid tumours of childhood. Ann Oncol. 1993; 4: 45–58, Suppl 1[PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Burdach S, van Kaick B, Laws H J. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors: an update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol. 2000; 11: 1451–1462, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Hoelle W. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?. J Clin Oncol. 2004; 22: 1696–1705, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Jones R J, Ambinder R F, Piantadosi S, Santos G W. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991; 77: 649–653, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mandingers C M, Meijerink J P, Raemaekers J M, Schattenberg A V, Mensink E J. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18). Lancet. 1998; 352: 1522–1523, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Childs R, Chernoff A, Contentin N. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000; 343: 750–758, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Koscielniak E, Klingebiel T H, Peters C. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/ Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant. 1997; 19: 227–231, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Maurer H M, Beltangady M, Gehan E A. The Intergroup Rhabdomyosarcoma Study, I: a final report. Cancer. 1988; 61: 209–220, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Koscielniak E, Jurgens H, Winkler K. Treatment of soft tissue sarcoma in childhood and adolescence: a report of the German Cooperative Soft Tissue Sarcoma Study. Cancer. 1992; 70: 2557–2567, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Flamant F, Hill C. The improvement in survival associated with combined chemotherapy in childhood rhabdomyosarcoma: a historical comparison of 345 patients in the same center. Cancer. 1984; 53: 2417–2421, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Carli M, Colombatti R, Oberlin O. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol. 1999; 17: 2796–2803, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chan K W, Rogers P C, Fryer C J. Breast metastases after bone marrow transplantation for rhabdomyosarcoma. Bone Marrow Transplant. 1991; 7: 171–172, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Bader P, Hancock J, Kreyenberg H. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia. 2002; 16: 1668–1672, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar